Utility of HoxB13 in differential diagnosis of female genital tract lesions with putative prostatic differentiation
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61383082%3A_____%2F25%3A00001569" target="_blank" >RIV/61383082:_____/25:00001569 - isvavai.cz</a>
Result on the web
<a href="https://pubmed.ncbi.nlm.nih.gov/41335140/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/41335140/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00428-025-04360-7" target="_blank" >10.1007/s00428-025-04360-7</a>
Alternative languages
Result language
angličtina
Original language name
Utility of HoxB13 in differential diagnosis of female genital tract lesions with putative prostatic differentiation
Original language description
Female genital tract lesions with putative prostatic differentiation include vaginal tubulosquamous polyp (TSP), cervical ectopic prostatic tissue (EPT), and adenoid basal carcinoma (ABC). HoxB13 is a transcription factor specific for the prostate, not previously assessed in these lesions. A cohort of 13 TSPs, 6 EPTs, 17 ABCs, and 8 adenoid basal hyperplasia (ABH) was analyzed for expression of prostatic markers HoxB13, NKX3.1, p16, and androgen receptor (AR). Additional 28 cervical high-grade squamous intraepithelial lesions (HSILs), 21 cervical squamous cell carcinomas (SCCs), 19 endocervical adenocarcinomas (EACs), and 10 endometrial endometrioid adenocarcinomas (ECs) were included. The results were recorded as immunoreactive score (IRS). In TSPs and EPTs, HoxB13 and NKX3.1 were positive in 100% and 89.5% of cases, respectively. No HoxB13, NKX3.1, and p16 was observed in ABHs. In contrast, all ABCs showed diffuse p16 positivity. NKX3.1 was positive in 82.6% of ABCs (median IRS = 2), HoxB13 was positive in 100% of ABCs (median IRS = 8), and the difference was statistically significant (p < 0.001). Both HoxB13 and NKX3.1 were positive in 9.5% (2/21) SCCs and 21.1% (4/19) EACs. Additionally, 40% (4/10) ECs were HoxB13-positive (IRS = 1–2). Any positivity of HoxB13 was 80% specific and 100% sensitive for the ABC. NKX3.1 was only 82.4% sensitive, but 88% specific for the diagnosis of ABC. Additionally, HoxB13 was also seen in 29.8% HSILs. No ABC showed AR positivity, while this was observed in rare cells (IRS 1–2) in 30.8%, 16.6%, and 37.5% of TSCs, EPTs, and ABHs, respectively. HoxB13 can be a useful and reliable marker for identification of TSPs, EPTs and ABCs.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30109 - Pathology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
VIRCHOWS ARCHIV
ISSN
0945-6317
e-ISSN
—
Volume of the periodical
2025
Issue of the periodical within the volume
Dec
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
1-10
UT code for WoS article
001634398900001
EID of the result in the Scopus database
2-s2.0-105023984960